Two hundred and forty-eight consecutively recruited patients attending a general psychiatry clinic with a wide variety of psychiatric disorders were treated with fluoxetine for a minimum of 3 months. Fluoxetine was shown to be effective and well-tolerated in a number of conditions of which only 57 per cent were major depressive disorder. Specific conditions and/or the presence of co-morbid Conditions believed to be due to underlying disturbances in serotonin metabolism were associated with a significantly enhanced response. In contrast, significantly more patients who did not have such morbidity or co-morbidity appeared to be made worse by treatment with fluoxetine. The implications of this for clinical practice are discussed.KEY WORDS -naturalistic; fluoxetine; serotonin
INTRODUCTIONIn the last few years a number of new antidepressants have appeared which have a preferential mode of action at specific monoamine receptor sites. Whereas all these drugs have been demonstrated in randomized controlled trials (RCTs) as having clinical efficacy as antidepressants (and in some cases other conditions as well) it is by no means clear whether there is any clinical advantage in using one drug over any other or for using a drug which is specific for serotonin, noradrenaline, or a combination of both. Comparison drug trials are few in number and, apart from the issue of sideeffects and safety in overdose, clinical guidelines for selecting one class of antidepressant in preference to another are currently lacking.Parallel with these pharmacological developments there has been a considerable advance in our understanding of the role of serotonin (5HT) in many psychiatric disorders. A number of these were reviewed by Lopez-Ibor in 1988 but since that time the list has grown. This has been matched by an increasing use by clinicians of SSRIs in conditions which lie outside of their current licensed